Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

TACT Trial Management Group; Paul Ellis; Peter Barrett-Lee; Lindsay Johnson; David Cameron; Andrew Wardley; Susan O'Reilly; Mark Verrill; Ian Smith; John Yarnold; Robert Coleman; Helena Earl; Peter Canney; Chris Twelves; Christopher Poole; David Bloomfield; Penelope Hopwood; Stephen Johnston; Mitchell Dowsett; John M S Bartlett; Ian Ellis; Clare Peckitt; Emma Hall; Judith M Bliss

doi:10.1016/S0140-6736(09)60740-6

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

TACT Trial Management Group, Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, David Cameron, Andrew Wardley, Susan O'Reilly, Mark Verrill, Ian Smith, John Yarnold, Robert Coleman, Helena Earl, Peter Canney, Chris Twelves, Christopher Poole, David Bloomfield, Penelope Hopwood, Stephen Johnston, Mitchell Dowsett, John M S BartlettIan Ellis, Clare Peckitt, Emma Hall, Judith M Bliss

Research output: Contribution to journal › Article › peer-review

Abstract

Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.

Original language	English
Pages (from-to)	1681-92
Number of pages	12
Journal	The Lancet
Volume	373
Issue number	9676
DOIs	https://doi.org/10.1016/S0140-6736(09)60740-6
Publication status	Published - 2009

Access to Document

10.1016/S0140-6736(09)60740-6

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Available under Open Access. Copyright © 2013 Elsevier B.V. All rights reserved.
Final published version, 290 KB

http://www.sciencedirect.com/science/article/pii/S0140673609607406

Cite this

TACT Trial Management Group, Ellis, P., Barrett-Lee, P., Johnson, L., Cameron, D., Wardley, A., O'Reilly, S., Verrill, M., Smith, I., Yarnold, J., Coleman, R., Earl, H., Canney, P., Twelves, C., Poole, C., Bloomfield, D., Hopwood, P., Johnston, S., Dowsett, M., ... Bliss, J. M. (2009). Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. The Lancet, 373(9676), 1681-92. https://doi.org/10.1016/S0140-6736(09)60740-6

@article{98ab1c26da2c4c8593483bb120d0cc5b,

title = "Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial",

abstract = "Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.",

author = "{TACT Trial Management Group} and Paul Ellis and Peter Barrett-Lee and Lindsay Johnson and David Cameron and Andrew Wardley and Susan O'Reilly and Mark Verrill and Ian Smith and John Yarnold and Robert Coleman and Helena Earl and Peter Canney and Chris Twelves and Christopher Poole and David Bloomfield and Penelope Hopwood and Stephen Johnston and Mitchell Dowsett and Bartlett, {John M S} and Ian Ellis and Clare Peckitt and Emma Hall and Bliss, {Judith M}",

year = "2009",

doi = "10.1016/S0140-6736(09)60740-6",

language = "English",

volume = "373",

pages = "1681--92",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9676",

}

TACT Trial Management Group, Ellis, P, Barrett-Lee, P, Johnson, L, Cameron, D, Wardley, A, O'Reilly, S, Verrill, M, Smith, I, Yarnold, J, Coleman, R, Earl, H, Canney, P, Twelves, C, Poole, C, Bloomfield, D, Hopwood, P, Johnston, S, Dowsett, M, Bartlett, JMS, Ellis, I, Peckitt, C, Hall, E & Bliss, JM 2009, 'Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial', The Lancet, vol. 373, no. 9676, pp. 1681-92. https://doi.org/10.1016/S0140-6736(09)60740-6

TY - JOUR

T1 - Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

T2 - an open-label, phase III, randomised controlled trial

AU - TACT Trial Management Group

AU - Ellis, Paul

AU - Barrett-Lee, Peter

AU - Johnson, Lindsay

AU - Cameron, David

AU - Wardley, Andrew

AU - O'Reilly, Susan

AU - Verrill, Mark

AU - Smith, Ian

AU - Yarnold, John

AU - Coleman, Robert

AU - Earl, Helena

AU - Canney, Peter

AU - Twelves, Chris

AU - Poole, Christopher

AU - Bloomfield, David

AU - Hopwood, Penelope

AU - Johnston, Stephen

AU - Dowsett, Mitchell

AU - Bartlett, John M S

AU - Ellis, Ian

AU - Peckitt, Clare

AU - Hall, Emma

AU - Bliss, Judith M

PY - 2009

Y1 - 2009

N2 - Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.

AB - Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.

UR - http://www.scopus.com/inward/record.url?scp=65549146500&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)60740-6

DO - 10.1016/S0140-6736(09)60740-6

M3 - Article

C2 - 19447249

SN - 1474-547X

VL - 373

SP - 1681

EP - 1692

JO - The Lancet

JF - The Lancet

IS - 9676

ER -

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this